NCT07690917 A Study of a New PET Scanner in People With Cancer
| NCT ID | NCT07690917 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Non Small Cell Lung Carcinoma NSCLC |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-06-30 |
| Primary Completion | 2029-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2026-06-30 with a primary completion date of 2029-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn whether this scanner can produce better PET/CT images and provide more useful imaging information than standard PET/CT scanners.
Eligibility Criteria
Inclusion Criteria: Eligibility Criteria for objective #1: * Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules. * Patients who are undergoing a planned PET-CT scan at main campus of MSK. * Patients must be ≥ 18 years old Eligibility Criteria for objective #2: * Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously. * Patients with metastatic prostate or head and neck cancer. * Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK. * Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK * Patients must be ≥ 18 years old Eligibility Criteria for objective #3: * Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer). * Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an \[18F\]-fluormisonidazole PET-CT scan at the main campus of MSK. * Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection) * Patients must be ≥ 18 years old Eligibility Criteria for objective #4: * Patients who are undergoing a planned PET-CT scan at main campus of MSK with a radiotracer * Patients must be ≥ 18 years old Exclusion Criteria: * Patients who suffer from claustrophobia. * Women who are pregnant or breast-feeding. * Patients \< 18 years of age
Contact & Investigator
Heiko Schoder, MD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT07690917 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non Small Cell Lung Carcinoma NSCLC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07690917 currently recruiting?
Yes, NCT07690917 is actively recruiting participants. Contact the research team at schoderh@mskcc.org for enrollment information.
Where is the NCT07690917 trial being conducted?
This trial is being conducted at Basking Ridge, United States, Middletown, United States, Montvale, United States, Commack, United States and 3 additional locations.
Who is sponsoring the NCT07690917 clinical trial?
NCT07690917 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Heiko Schoder, MD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 90 participants.